Biologics/Immunotherapy News

Among other roles, Kelly Maples, MD, can now count herself among the members of Healio’s Allergy/Asthma Peer Perspective Board.

Patients with chronic rhinosinusitis with nasal polyps tolerated treatment with biologics with decreased risks for asthma exacerbation and worsening nasal polyps, according to a study published in Clinical and Translational Allergy.

Patients with asthma, chronic rhinosinusitis with nasal polyps and atopic dermatitis experienced transient increases in eosinophil counts following treatment with dupilumab, according to study results.

Factors such as administration setting and demographics impacted adherence to biologic treatment among patients with moderate to severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The use of H1 or H2 antihistamines may mitigate some side effects of peanut oral immunotherapy, but they did not influence quality of life, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in adults and children aged 12 years and older, making it the first drug in the U.S. specifically indicated for this condition.

Fixed-dose OIT appeared safe and effective for younger children with high-threshold peanut allergy, according to a single-center, cross-sectional prospective study published in Annals of Allergy, Asthma & Immunology.

As the medical community celebrates Asthma and Allergy Awareness Month this May, the American College of Allergy, Asthma & Immunology reminds clinicians and patients alike that allergists are key to successful asthma treatment.

By inhibiting IL-4R alpha in aspirin-exacerbated respiratory disease, dupilumab improved respiratory symptoms and smell among other positive outcomes, according to a study published in The Journal of Allergy and Clinical Immunology.

Peanut oral immunotherapy presents clinical and economic concerns and may not be necessary for children with good quality of life, according to an editorial by Michael R. Perkin, MB BS (Hons), PhD.